Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.07.2015 | case report

Osteogenesis imperfecta type III and hypogonadotropic hypogonadism result in severe bone loss: a case report

verfasst von: Fabian Plachel, MD, Ursula Renner, MD, Roland Kocijan, MD, Christian Muschitz, MD, Univ. Doz. Fritz Lomoschitz, MD, Prof. Heinrich Resch, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 13-14/2015

Einloggen, um Zugang zu erhalten

Summary

We present the case of a 33-year-old male patient with multiple fractures and typical radiographical and clinical characteristics of osteogenesis imperfecta (OI) type III. Furthermore, the patient has suffered from hypogonadotropic hypogonadism since childhood. On the basis of antiresorptive therapy, no further fractures occurred within several years. Recently, recurrent nontraumatic fractures without bone healing were observed. Decreased bone mineral density was assessed by dual X-ray absorptiometry (DXA). High-resolution peripheral quantitative computed tomography (HR-pQCT) showed impaired trabecular bone structure. Due to recurrent fragility fractures and severe deterioration of bone structure, an osteoanabolic treatment with teriparatide was initiated to potentially stimulate fracture healing and to increase bone formation.
Vorheriger Artikel Osteogenesis imperfecta: pathophysiology and treatment
Nächster Artikel Frühsommer-Meningo-Enzephalitis (FSME) und FSME-Schutzimpfung in Österreich: Update 2014
Literatur
1.
Lindahl K, Langdahl B, Ljunggren O, Kindmark A. Treatment of osteogenesis imperfecta in adults. Eur J Endocrinol. 2014;171:R79–90.PubMedCrossRef
2.
Garbes L, Kim K, Riess A, Hoyer-Kuhn H, Beleggia F, Bevot A, et al. Mutations in SEC24D, encoding a component of the COPII machinery, cause a syndromic form of osteogenesis imperfecta. Am J Hum Genet. 2015;96:432–9.PubMedCrossRef
3.
4.
Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res. 2006;21:300–6.PubMedCrossRef
5.
Kocijan R, Muschitz C, Fahrleitner-Pammer A, Amrein K, Pietschmann P, Haschka J, et al. Serum sclerostin levels are decreased in adult patients with different types of osteogenesis imperfecta. J Clin Endocrinol Metab. 2014;99:E311–9.PubMedCrossRef
6.
Fritez N, Sobrier ML, Iraqi H, Vie-Luton MP, Netchine I, El Annas A, et al. Molecular screening of a large cohort of Moroccan patients with congenital hypopituitarism. Clin Endocrinol (Oxf). 2015;82:876–84.CrossRef
7.
Mehta A, Hindmarsh PC, Mehta H, Turton JP, Russell-Eggitt I, Taylor D, et al. Congenital hypopituitarism: clinical, molecular and neuroradiological correlates. Clin Endocrinol (Oxf). 2009;71:376–82.CrossRef
8.
Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001;16:398–405.PubMedCrossRef
9.
Vieira da Costa J, Pereira-Lima JF, da Costa Oliveira M. Bone mineral density in early-onset hypogonadism and the effect of hormonal replacement. J Clin Densitom. 2004;7:334–40.PubMedCrossRef
10.
Paterson CR, McAllion S, Stellman JL. Osteogenesis imperfecta after the menopause. N Engl J Med. 1984;310:1694–6.PubMedCrossRef
11.
Hald JD, Evangelou E, Langdahl BL, Ralston SH. Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials. J Bone Miner Res. 2015;30:929–33.PubMedCrossRef
12.
Kocijan R, Haschka J, Muschitz C, Trubrich A, Patsch J, Resch H. Enhanced callus formation after six weeks of parathyroid hormone treatment in a man with multiple pelvic fractures and osteogenesis imperfecta type IV. J Bone Joint Surg Am. 2012;2(4):e74. http://​dx.​doi.​org/​10.​2106/​JBJS.​CC.​L.​00042.
13.
Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124:491–8.PubMedCentralPubMedCrossRef
14.
Gatti D, Rossini M, Viapiana O, Povino MR, Liuzza S, Fracassi E, et al. Teriparatide treatment in adult patients with osteogenesis imperfecta type I. Calcif Tissue Int. 2013;93:448–52.PubMedCrossRef
15.
Antoniazzi F, Monti E, Venturi G, Franceschi R, Doro F, Gatti D, et al. GH in combination with bisphosphonate treatment in osteogenesis imperfecta. Eur J Endocrinol. 2010;163:479–87.PubMedCrossRef
16.
O’Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab. 1993;76:1344–8.
17.
Scott CI, Mengel MC, Lawrence GD, Schultz KT, Edgar PJ. Osteogenesis imperfecta and hypopituitarism in two unrelated males. Birth Defects Orig Artic Ser. 1971;7:259–62.
18.
Kocijan R, Muschitz C, Haschka J, Hans D, Nia A, Geroldinger A, et al. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta. Osteoporos Int. 2015. [Epub ahead of print].
Metadaten
Titel
Osteogenesis imperfecta type III and hypogonadotropic hypogonadism result in severe bone loss: a case report
verfasst von
Fabian Plachel, MD
Ursula Renner, MD
Roland Kocijan, MD
Christian Muschitz, MD
Univ. Doz. Fritz Lomoschitz, MD
Prof. Heinrich Resch, MD
Publikationsdatum
01.07.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 13-14/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-015-0367-4

Weitere Artikel der Ausgabe 13-14/2015

Classification of osteogenesis imperfecta

  • main topic

Osteogenesis imperfecta: pathophysiology and treatment

  • main topic

Osteogenesis imperfecta: from bench to bedside

  • editorial

Frühsommer-Meningo-Enzephalitis (FSME) und FSME-Schutzimpfung in Österreich: Update 2014

  • kurzbericht

Bone mass and mineralization in osteogenesis imperfecta

  • main topic